Jump to content

Pelanserin

From Wikipedia, the free encyclopedia
Pelanserin
Names
Preferred IUPAC name
3-[3-(4-Phenylpiperazin-1-yl)propyl]quinazoline-2,4(1H,3H)-dione
Other names
TR2515
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
    Key: WPKPLSFHHBBLRY-UHFFFAOYSA-N
  • InChI=1/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
    Key: WPKPLSFHHBBLRY-UHFFFAOYAV
  • C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC=CC=C4
Properties
C21H24N4O2
Molar mass 364.449 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Pelanserin (TR2515) is a chemical compound that acts as an antagonist of the 5-HT2 and α1-adrenergic receptors.[1]

Synthesis

[edit]
Synthesis of pelanserin

Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.[2][3][4][5][6][7][8][9]

See also

[edit]

References

[edit]
  1. ^ Villalobos-Molina, R; Ibarra, M; Hong, E (1995). "The 5-HT2 receptor antagonist, pelanserin, inhibits alpha 1-adrenoceptor-mediated vasoconstriction in vitro". European Journal of Pharmacology. 277 (2–3): 181–5. doi:10.1016/0014-2999(95)00074-u. PMID 7493607.
  2. ^ Hayao, Shin; Havera, Herbert J.; Strycker, Wallace G.; Leipzig, T. J.; Kulp, Richard A.; Hartzler, Harold E. (1965). "New Sedative and Hypotensive 3-Substituted 2,4(1H,3H)-Quinazolinediones". Journal of Medicinal Chemistry. 8 (6): 807–811. doi:10.1021/jm00330a017. PMID 5885076.
  3. ^ Havera, Herbert J.; Vidrio, H. (1979). "Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents". Journal of Medicinal Chemistry. 22 (12): 1548–1550. doi:10.1021/jm00198a024. PMID 231656.
  4. ^ Garcia, J. D.; Somanathan, R.; Rivero, I. A.; Aguirre, G.; Hellberg, L. H. (2000). "Synthesis of Deuterium-Labeled Antihypertensive 3-(4-Phenyl-1′-Piperazinyl)-Propyl-2,4-Quinazolinedione". Synthetic Communications. 30 (15): 2707–2711. doi:10.1080/00397910008086895.
  5. ^ . doi:10.5012/bkcs.2011.32.9.3480. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  6. ^ Cortez, R.; Rivero, I. A.; Somanathan, R.; Aguirre, G.; Ramirez, F.; Hong, E. (1991). "Synthesis of Quinazolinedione Using Triphosgene". Synthetic Communications. 21 (2): 285–292. doi:10.1080/00397919108020823.
  7. ^ AT 269143B, "Verfahren zur Herstellung von neuen Chinazolindionderivaten und ihrer Säureadditionssalze bzw. ihrer entsprechenden Piperaziniumverbindungen [Process for the preparation of new quinazolinedione derivatives and their acid addition salts or their corresponding piperazinium compounds]", published 1969-03-10, assigned to Miles Laboratories, Inc. 
  8. ^ Hayao Shin, U.S. patent 3,274,194 (1966 to Bayer Corp)
  9. ^ Horacio Vidrio, U.S. patent 3,919,425 (1975 to Bayer Corp).